_id
69109352ccc777a4e85d5a3a
Ticker
EBS
Name
Emergent Biosolutions Inc
Exchange
NYSE
Address
300 Professional Drive, Gaithersburg, MD, United States, 20879
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.emergentbiosolutions.com
Description
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Last Close
11.72
Volume
346920
Current Price
11.41
Change
-2.645051194539253
Last Updated
2025-11-29T12:31:15.142Z
Image
-
Ipo Date
2006-11-15T00:00:00.000Z
Market Cap
595931776
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9952500000000001
Sentiment Sources
8
Rating
3.6667
Target Price
13.5
Strong Buy
1
Buy
1
Hold
0
Sell
1
Strong Sell
0
Current Quarter
2025-09-30
Revenue
231100000
Cost Of Revenue
91700000
Gross Profit
139400000
Operating Expenses
62900000
Operating Income
76500000
Interest Expense
15200000
Pretax Income
57600000
Net Income
51200000
Eps
0.9061946902654867
Dividends Per Share
-
Shares Outstanding
52519964
Income Tax Expense
6400000
EBITDA
96200000
Operating Margin
33.10255300735612
Total Other Income Expense Net
-18900000
Cash
245500000
Short Term Investments
-
Receivables
149500000
Inventories
356300000
Total Current Assets
786900000
Property Plant Equipment
209800000
Total Assets
1461000000
Payables
57400000
Short Term Debt
-
Long Term Debt
663100000
Total Liabilities
878500000
Equity
582500000
Depreciation
23400000
Change In Working Capital
-81400000
Cash From Operations
-2300000
Capital Expenditures
3400000
Cash From Investing
-3400000
Cash From Financing
-15900000
Net Change In Cash
-21800000
PE
8.4621
PB
1.1173905579399142
ROE
8.78969957081545
ROA
3.5044490075290895
FCF
-5700000
Fcf Percent
-0.024664647338814367
Piotroski FScore
2
Health Score
49
Deep Value Investing Score
6
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
5.8
Garp Investing Score
3.5
Growth Investing Score
3
Momentum Investing Score
6
Net Net Investing Score
1.5
Quality Investing Score
5.5
Value Investing Score
8.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
231100000
Quarters > 0 > income Statement > cost Of Revenue
91700000
Quarters > 0 > income Statement > gross Profit
139400000
Quarters > 0 > income Statement > operating Expenses
62900000
Quarters > 0 > income Statement > operating Income
76500000
Quarters > 0 > income Statement > interest Expense
15200000
Quarters > 0 > income Statement > pretax Income
57600000
Quarters > 0 > income Statement > net Income
51200000
Quarters > 0 > income Statement > eps
0.9061946902654867
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
56500000
Quarters > 0 > income Statement > income Tax Expense
6400000
Quarters > 0 > income Statement > EBITDA
96200000
Quarters > 0 > income Statement > operating Margin
33.10255300735612
Quarters > 0 > income Statement > total Other Income Expense Net
-18900000
Quarters > 0 > balance Sheet > cash
245500000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
149500000
Quarters > 0 > balance Sheet > inventories
356300000
Quarters > 0 > balance Sheet > total Current Assets
786900000
Quarters > 0 > balance Sheet > property Plant Equipment
209800000
Quarters > 0 > balance Sheet > total Assets
1461000000
Quarters > 0 > balance Sheet > payables
57400000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
663100000
Quarters > 0 > balance Sheet > total Liabilities
878500000
Quarters > 0 > balance Sheet > equity
582500000
Quarters > 0 > cash Flow > net Income
51200000
Quarters > 0 > cash Flow > depreciation
23400000
Quarters > 0 > cash Flow > change In Working Capital
-81400000
Quarters > 0 > cash Flow > cash From Operations
-2300000
Quarters > 0 > cash Flow > capital Expenditures
3400000
Quarters > 0 > cash Flow > cash From Investing
-3400000
Quarters > 0 > cash Flow > cash From Financing
-15900000
Quarters > 0 > cash Flow > net Change In Cash
-21800000
Quarters > 0 > ratios > PE
0.9061946902654867
Quarters > 0 > ratios > PB
1.1173905579399142
Quarters > 0 > ratios > ROE
8.78969957081545
Quarters > 0 > ratios > ROA
3.5044490075290895
Quarters > 0 > ratios > FCF
-5700000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-0.024664647338814367
Quarters > 0 > health Score
49
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
140900000
Quarters > 1 > income Statement > cost Of Revenue
80200000
Quarters > 1 > income Statement > gross Profit
60700000
Quarters > 1 > income Statement > operating Expenses
59100000
Quarters > 1 > income Statement > operating Income
1600000
Quarters > 1 > income Statement > interest Expense
14700000
Quarters > 1 > income Statement > pretax Income
-16800000
Quarters > 1 > income Statement > net Income
-12000000
Quarters > 1 > income Statement > eps
-0.22140221402214022
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
54200000
Quarters > 1 > income Statement > income Tax Expense
-4800000
Quarters > 1 > income Statement > EBITDA
23500000
Quarters > 1 > income Statement > operating Margin
1.1355571327182399
Quarters > 1 > income Statement > total Other Income Expense Net
-18400000
Quarters > 1 > balance Sheet > cash
271000000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
79800000
Quarters > 1 > balance Sheet > inventories
338600000
Quarters > 1 > balance Sheet > total Current Assets
719500000
Quarters > 1 > balance Sheet > property Plant Equipment
223800000
Quarters > 1 > balance Sheet > total Assets
1417100000
Quarters > 1 > balance Sheet > payables
63700000
Quarters > 1 > balance Sheet > short Term Debt
1800000
Quarters > 1 > balance Sheet > long Term Debt
667800000
Quarters > 1 > balance Sheet > total Liabilities
880900000
Quarters > 1 > balance Sheet > equity
536200000
Quarters > 1 > cash Flow > net Income
-12000000
Quarters > 1 > cash Flow > depreciation
23500000
Quarters > 1 > cash Flow > change In Working Capital
95700000
Quarters > 1 > cash Flow > cash From Operations
106400000
Quarters > 1 > cash Flow > capital Expenditures
2900000
Quarters > 1 > cash Flow > cash From Investing
17200000
Quarters > 1 > cash Flow > cash From Financing
-6400000
Quarters > 1 > cash Flow > net Change In Cash
118200000
Quarters > 1 > ratios > PE
-0.22140221402214022
Quarters > 1 > ratios > PB
1.164461022006714
Quarters > 1 > ratios > ROE
-2.237970906378217
Quarters > 1 > ratios > ROA
-0.8467998024133795
Quarters > 1 > ratios > FCF
103500000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
0.7345635202271115
Quarters > 1 > health Score
44
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
222200000
Quarters > 2 > income Statement > cost Of Revenue
102800000
Quarters > 2 > income Statement > gross Profit
119400000
Quarters > 2 > income Statement > operating Expenses
69500000
Quarters > 2 > income Statement > operating Income
49900000
Quarters > 2 > income Statement > interest Expense
14700000
Quarters > 2 > income Statement > pretax Income
92700000
Quarters > 2 > income Statement > net Income
68000000
Quarters > 2 > income Statement > eps
1.1867364746945899
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
57300000
Quarters > 2 > income Statement > income Tax Expense
24700000
Quarters > 2 > income Statement > EBITDA
75200000
Quarters > 2 > income Statement > operating Margin
22.45724572457246
Quarters > 2 > income Statement > total Other Income Expense Net
42800000
Quarters > 2 > balance Sheet > cash
149100000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
203700000
Quarters > 2 > balance Sheet > inventories
314000000
Quarters > 2 > balance Sheet > total Current Assets
706800000
Quarters > 2 > balance Sheet > property Plant Equipment
221000000
Quarters > 2 > balance Sheet > total Assets
1426100000
Quarters > 2 > balance Sheet > payables
58100000
Quarters > 2 > balance Sheet > short Term Debt
0
Quarters > 2 > balance Sheet > long Term Debt
665700000
Quarters > 2 > balance Sheet > total Liabilities
873400000
Quarters > 2 > balance Sheet > equity
552700000
Quarters > 2 > cash Flow > net Income
68000000
Quarters > 2 > cash Flow > depreciation
25400000
Quarters > 2 > cash Flow > change In Working Capital
-118700000
Quarters > 2 > cash Flow > cash From Operations
-11200000
Quarters > 2 > cash Flow > capital Expenditures
3600000
Quarters > 2 > cash Flow > cash From Investing
59500000
Quarters > 2 > cash Flow > cash From Financing
-400000
Quarters > 2 > cash Flow > net Change In Cash
47200000
Quarters > 2 > ratios > PE
1.1867364746945899
Quarters > 2 > ratios > PB
1.194311561425728
Quarters > 2 > ratios > ROE
12.303238646643749
Quarters > 2 > ratios > ROA
4.768249070892644
Quarters > 2 > ratios > FCF
-14800000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-0.0666066606660666
Quarters > 2 > health Score
53
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
194700000
Quarters > 3 > income Statement > cost Of Revenue
58200000
Quarters > 3 > income Statement > gross Profit
136500000
Quarters > 3 > income Statement > operating Expenses
146000000
Quarters > 3 > income Statement > operating Income
-9500000
Quarters > 3 > income Statement > interest Expense
14800000
Quarters > 3 > income Statement > pretax Income
-27600000
Quarters > 3 > income Statement > net Income
-31300000
Quarters > 3 > income Statement > eps
-0.577490774907749
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
54200000
Quarters > 3 > income Statement > income Tax Expense
3700000
Quarters > 3 > income Statement > EBITDA
21000000
Quarters > 3 > income Statement > operating Margin
-4.879301489470981
Quarters > 3 > income Statement > total Other Income Expense Net
-18100000
Quarters > 3 > balance Sheet > cash
105600000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
154500000
Quarters > 3 > balance Sheet > inventories
311700000
Quarters > 3 > balance Sheet > total Current Assets
598700000
Quarters > 3 > balance Sheet > property Plant Equipment
282300000
Quarters > 3 > balance Sheet > total Assets
1396900000
Quarters > 3 > balance Sheet > payables
60900000
Quarters > 3 > balance Sheet > short Term Debt
2700000
Quarters > 3 > balance Sheet > long Term Debt
663700000
Quarters > 3 > balance Sheet > total Liabilities
914100000
Quarters > 3 > balance Sheet > equity
482800000
Quarters > 3 > cash Flow > net Income
-31300000
Quarters > 3 > cash Flow > depreciation
26000000
Quarters > 3 > cash Flow > change In Working Capital
-85300000
Quarters > 3 > cash Flow > cash From Operations
-79900000
Quarters > 3 > cash Flow > capital Expenditures
1700000
Quarters > 3 > cash Flow > cash From Investing
28600000
Quarters > 3 > cash Flow > cash From Financing
500000
Quarters > 3 > cash Flow > net Change In Cash
-50800000
Quarters > 3 > ratios > PE
-0.577490774907749
Quarters > 3 > ratios > PB
1.2932560066280032
Quarters > 3 > ratios > ROE
-6.483015741507871
Quarters > 3 > ratios > ROA
-2.2406757820889114
Quarters > 3 > ratios > FCF
-81600000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-0.41910631741140214
Quarters > 3 > health Score
24
Valuation > metrics > PE
8.4621
Valuation > metrics > PB
1.1173905579399142
Valuation > final Score
100
Valuation > verdict
7.7% Undervalued
Profitability > metrics > ROE
8.78969957081545
Profitability > metrics > ROA
6.506544668954124
Profitability > metrics > Net Margin
0.22154911293812202
Profitability > final Score
67
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
1.5081545064377682
Risk > metrics > Interest Coverage
5.032894736842105
Risk > final Score
50
Risk > verdict
High
Liquidity > metrics > Current Ratio
13.709059233449477
Liquidity > metrics > Quick Ratio
7.501742160278746
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
100
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
83
Prev Profitabilities > 2
0
Prev Risks > 0
30
Prev Risks > 1
44
Prev Risks > 2
27
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T16:07:45.270Z
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AEmergent BioSolutions (NYSE: EBS) gains FDA OK for Winnipeg raxibacumab drug product site Stock Titan
Read more →Elbstein AG EBS Stock Analysis and Forecast - Low Beta Stocks & Affordable Investment Portfolio earlytimes.in
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$13.5
Analyst Picks
Strong Buy
1
Buy
1
Hold
0
Sell
1
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 77.57% of the total shares of Emergent Biosolutions Inc
1.
BlackRock Inc(8.1739%)
since
2025/06/30
2.
Oak Hill Advisors LP(6.7728%)
since
2025/06/30
3.
Vanguard Group Inc(6.7182%)
since
2025/06/30
4.
American Century Companies Inc(4.2964%)
since
2025/06/30
5.
Avantis US Small Cap Value ETF(3.6145%)
since
2025/08/30
6.
Dimensional Fund Advisors, Inc.(3.4658%)
since
2025/06/30
7.
State Street Corp(3.2628%)
since
2025/06/30
8.
Vanguard Total Stock Mkt Idx Inv(2.9516%)
since
2025/07/31
9.
iShares Russell 2000 ETF(2.4498%)
since
2025/08/31
10.
Geode Capital Management, LLC(2.3973%)
since
2025/06/30
11.
Charles Schwab Investment Management Inc(2.0715%)
since
2025/06/30
12.
Palisade Capital Management LLc(2.0614%)
since
2025/06/30
13.
Marshall Wace Asset Management Ltd(1.9097%)
since
2025/06/30
14.
Connor Clark & Lunn Inv Mgmt Ltd(1.8494%)
since
2025/06/30
15.
SPDR® S&P Biotech ETF(1.7791%)
since
2025/08/31
16.
LSV Asset Management(1.5287%)
since
2025/06/30
17.
Prescott Group Capital Management LLC(1.4485%)
since
2025/06/30
18.
Millennium Management LLC(1.416%)
since
2025/06/30
19.
Morgan Stanley - Brokerage Accounts(1.3746%)
since
2025/06/30
20.
Palisade Small Cap Core Equity(1.2941%)
since
2025/06/30
21.
Renaissance Technologies Corp(1.2927%)
since
2025/06/30
22.
Vanguard Institutional Extnd Mkt Idx Tr(1.1045%)
since
2025/07/31
23.
Goldman Sachs Group Inc(1.086%)
since
2025/06/30
24.
Amvescap Plc.(1.0595%)
since
2025/06/30
25.
Pacer Advisors, INC.(1.0435%)
since
2025/06/30
26.
Trexquant Investment LP(1.0336%)
since
2025/06/30
27.
Fidelity Small Cap Index(1.0124%)
since
2025/06/30
28.
Schwab Fundamental U.S. Small CompanyETF(1.0118%)
since
2025/08/30
29.
Invesco RAFI US 1500 Small-Mid ETF(1.0053%)
since
2025/08/29
30.
Pacer US Small Cap Cash Cows 100 ETF(0.9422%)
since
2025/08/29
31.
iShares Russell 2000 Value ETF(0.9013%)
since
2025/08/31
32.
Vanguard Strategic Equity Inv(0.8722%)
since
2025/06/30
33.
DFA US Targeted Value I(0.7562%)
since
2025/07/31
34.
Dimensional US Targeted Value ETF(0.6071%)
since
2025/08/29
35.
iShares Biotechnology ETF(0.5797%)
since
2025/08/31
36.
Fidelity Extended Market Index(0.5471%)
since
2025/07/31
37.
Vanguard Russell 2000 ETF(0.4826%)
since
2025/07/31
38.
Schwab US Small-Cap ETFâ„¢(0.4819%)
since
2025/08/30
39.
Federated Hermes MDT SCC Institutional(0.4582%)
since
2025/06/30
40.
Federated Hermes MDT Small Cap Core IS(0.4582%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.